tbuckley/cabot-search huggingface dataset:
Inpatient Management of Type 2 Diabetes
Authors: Shane Warnock, Niloofar Latifi
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Novel frequency-based approach for detection of steady-state visual evoked potentials for realization of practical brain computer interfaces
Authors: Mehrnoosh Neghabi, Hamid Reza Marateb, Amin Mahnam
Journal: Brain-Computer Interfaces (2022)

Various algorithms for recognizing Steady-State Visual Evoked Potentials have been proposed over the last decade for realizing Brain-Computer Interfaces. However, frequency-domain techniques aside from classical FFT have been generally neglected. While close to perfect accuracies have been reported in SSVEP-based BCI studies, achieving high accuracy in a realistic scenario is still challenging. Here several frequency-domain algorithms were evaluated for SSVEP detection for the first time, and a new algorithm based on spectral averaging on resampled signal (SAoRS) was proposed, when a single EEG channel and high-frequency flickers were considered to improve user experience. Spectral Envelope (SE) and Maximum Entropy (ME) methods outperformed Burg, MUSIC, and Welch for processing window lengths of 0.5–2 s. The newly developed SAoRS algorithm significantly outperformed SE and the benchmark CCA algorithms for 0.5 s processing window. The results suggest that Spectral Envelop and SAoRS algorithms can provide high accuracies in SSVEP BCI systems.
Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo
Authors: Pavel Kolkhir, Polina Pyatilova, Tameem Ashry, Qingqing Jiao, Angela Teresa Abad-Perez, Sabine Altrichter, Carolina Elisa Vera Ayala, Martin K. Church, Jiajun He, Katharina Lohse, Martin Metz, Jörg Scheffel, Murat Türk, Stefan Frischbutter, Marcus Maurer
Journal: Journal of Allergy and Clinical Immunology (2022)
HIF-1α inhibitor PX-478 preserves pancreatic β cell function in diabetes
Authors: Erwin Ilegems, Galyna Bryzgalova, Jorge Correia, Burcak Yesildag, Edurne Berra, Jorge L. Ruas, Teresa S. Pereira, Per-Olof Berggren
Journal: Science Translational Medicine (2022)

During progression of type 2 diabetes, pancreatic β cells are subjected to sustained metabolic overload. We postulated that this state mediates a hypoxic phenotype driven by hypoxia-inducible factor-1α (HIF-1α) and that treatment with the HIF-1α inhibitor PX-478 would improve β cell function. Our studies showed that the HIF-1α protein was present in pancreatic β cells of diabetic mouse models. In mouse islets with high glucose metabolism, the emergence of intracellular Ca2+ oscillations at low glucose concentration and the abnormally high basal release of insulin were suppressed by treatment with the HIF-1α inhibitor PX-478, indicating improvement of β cell function. Treatment of db/db mice with PX-478 prevented the rise of glycemia and diabetes progression by maintenance of elevated plasma insulin concentration. In streptozotocin-induced diabetic mice, PX-478 improved the recovery of glucose homeostasis. Islets isolated from these mice showed hallmarks of improved β cell function including elevation of insulin content, increased expression of genes involved in β cell function and maturity, inhibition of dedifferentiation markers, and formation of mature insulin granules. In response to PX-478 treatment, human islet organoids chronically exposed to high glucose presented improved stimulation index of glucose-induced insulin secretion. These results suggest that the HIF-1α inhibitor PX-478 has the potential to act as an antidiabetic therapeutic agent that preserves β cell function under metabolic overload.
TO THIN OR NOT TO THIN: A “NOVEL” CASE OF SPONTANEOUS HEMORRHAGIC PERICARDIAL TAMPONADE COMPLICATED BY ACUTE CVA WITH INTRACARDIAC THROMBUS
Authors: Matthew C. McCurdy, Bashar Al Hemyari, Sajjad Haider, Jacqueline Dawson, Mohammed Kazimuddin, Aniruddha Singh
Journal: Journal of the American College of Cardiology (2022)
Genomic Epidemiology of Carbapenemase-Producing <i>Klebsiella Pneumoniae</i> in China
Authors: Cuidan Li, Xiaoyuan Jiang, Tingting Yang, Yingjiao Ju, Zhe Yin, Liya Yue, Guannan Ma, Xuebing Wang, Ying Jing, Xinhua Luo, Shuangshuang Li, Xue Yang, Fei Chen, Dongsheng Zhou
Journal: Genomics Proteomics & Bioinformatics (2022)

The rapid spread of carbapenemase-producing Klebsiella pneumoniae (cpKP) poses serious threats to public health; however, the underlying genetic basis for its dissemination is still unknown. We conducted a comprehensive genomic epidemiology analysis on 420 cpKP isolates collected from 70 hospitals in 24 provinces/autonomous regions/municipalities of China during 2009-2017 by short-/long-read sequencing. The results showed that most cpKP isolates were categorized into clonal group 258 (CG258), in which ST11 was the dominant clone. Phylogenetic analysis revealed three major clades including the top one of Clade 3 for CG258 cpKP isolates. Additionally, carbapenemase gene analysis indicated that blaKPC was dominant in the cpKP isolates, and most blaKPC genes were located in five major incompatibility (Inc) groups of blaKPC-harboring plasmids. Importantly, three advantageous combinations of host-blaKPC-carrying plasmid (Clade 3.1+3.2-IncFIIpHN7A8, Clade 3.1+3.2-IncFIIpHN7A8:IncR, and Clade 3.3-IncFIIpHN7A8:IncpA1763-KPC) were identified to confer cpKP isolates the advantages in both genotypes (strong correlation/coevolution) and phenotypes (resistance/growth/competition) to facilitate the nationwide spread of ST11/CG258 cpKP. Intriguingly, Bayesian skyline analysis illustrated that the three advantageous combinations might be directly associated with the strong population expansion during 2007-2008 and subsequent maintenance of the population of ST11/CG258 cpKP after 2008. We then examined drug resistance profiles of these cpKP isolates and proposed combination treatment regimens for CG258/non-CG258 cpKP infections. Thus, the findings of our systematical analysis shed light on the molecular epidemiology and genetic basis for the dissemination of ST11/CG258 cpKP in China, and much emphasis should be given to the close monitoring of advantageous cpKP-plasmid combinations.
FUNCTIONAL AND SYMPTOMATIC CLINICAL ENDPOINTS IN HEART FAILURE RESEARCH: INSIGHTS FROM THE HEART FAILURE COLLABORATORY (HFC) - ACADEMIC RESEARCH CONSORTIUM (ARC) SCIENTIFIC EXPERT PANEL
Authors: Matthew Dimond, Mona Fiuzat, Mitchell A. Psotka, Christopher M. O’Connor, Heart Failure Collaboratory-Academic Research Consortium, William T. Abraham, Tariq Ahmad, Stefan D. Anker, Michael G. Felker, Gerasimos Filippatos, Dalane W. Kitzman, Eric Leifer, Eldrin F. Lewis, JoAnn Lindenfeld, Robert John Mentz, Richard Nkulikiyinka, Dan Schaber, Abhinav Sharma, Scott D. Solomon, Norman Stockbridge, John R. Teerlink, David J. Whellan, Janet T. Wittes
Journal: Journal of the American College of Cardiology (2022)
Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study
Authors: Jason R Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, Shengjie Wu, Azra H Ligon, Neal Ian Lindeman, Anuradha Banerjee, Roger Packer, Lindsay B Kilburn, Ian F Pollack, Ibrahim A Qaddoumi, Paul Graham Fisher, Girish Dhall, Patricia Ann Baxter, Susan G Kreissman, L Austin Doyle, Malcolm A Smith, Maryam Fouladi, Ira J Dunkel
Journal: Neuro-Oncology (2022)
CAN YOU HEAR ME NOW? DIGITAL CARE UTILIZATION IS HIGHER IN OLDER ARRHYTHMIA PATIENTS UTILIZING TELEPHONE TECHNOLOGY
Authors: Katherine Sauer, Amy Leigh Miller, Jorge Enrique Romero, David Chang, Patrice Hoskins, Morgan Turner, Kenneth James Comeiro, Lindsay Harris, Julie B. Shea, Thomas M. Tadros, Paul C. Zei, Sunil Kapur, Usha B. Tedrow, David T. Martin, Omar Kreidieh, William H. Sauer, Bruce A. Koplan
Journal: Journal of the American College of Cardiology (2022)
LOW-OUTPUT CHYLOTHORAX FOLLOWING A CORONARY ARTERY-BYPASS SURGERY &amp; SURGICAL AORTIC VALVE REPLACEMENT
Authors: Jonathan Benitez Gonzalez, Andres Garcia Berrios, Alejandro Quilichini, Jonathan Cordero-Jiménez, Erika Ortiz-Chaparro, Hilton Franqui-Rivera
Journal: Journal of the American College of Cardiology (2022)
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer
Authors: Iván Pérez-Núñez, Catalina Rozalén, José Ángel Palomeque, Irene Sangrador, Mariona Dalmau, Laura Comerma, Anna Hernández-Prat, David Casadevall, Silvia Menendez, Daniel Dan Liu, Minhong Shen, Jordi Berenguer, Irene Rius Ruiz, Raul Peña, José Carlos Montañés, M. Mar Albà, Sarah Bonnin, Julia Ponomarenko, Roger R. Gomis, Juan Miguel Cejalvo, Sonia Servitja, Diego M. Marzese, Lluis Morey, Leonie Voorwerk, Joaquín Arribas, Begoña Bermejo, Marleen Kok, Lajos Pusztai, Yibin Kang, Joan Albanell, Toni Celià-Terrassa
Journal: Nature Cancer (2022)
Reducing ischemic kidney injury through application of a synchronization modulation electric field to maintain Na <sup>+</sup> /K <sup>+</sup> -ATPase functions
Authors: Wei Chen, Lei Wang, Pengfei Liang, Jason Mast, Clausell Mathis, Catherine Y. Liu, Jin Wei, Jie Zhang, Liying Fu, Luis A. Juncos, Jacentha Buggs, Ruisheng Liu
Journal: Science Translational Medicine (2022)

Renal ischemia-reperfusion injury is an important contributor to the development of delayed graft function after transplantation, which is associated with higher rejection rates and poorer long-term outcomes. One of the earliest impairments during ischemia is Na + /K + -ATPase (Na/K pump) dysfunction due to insufficient ATP supply, resulting in subsequent cellular damage. Therefore, strategies that preserve ATP or maintain Na/K pump function may limit the extent of renal injury during ischemia-reperfusion. Here, we applied a synchronization modulation electric field to activate Na/K pumps, thereby maintaining cellular functions under ATP-insufficient conditions. We tested the effectiveness of this technique in two models of ischemic renal injury: an in situ renal ischemia-reperfusion injury model (predominantly warm ischemia) and a kidney transplantation model (predominantly cold ischemia). Application of the synchronization modulation electric field to a renal ischemia-reperfusion injury mouse model preserved Na/K pump activity, thereby reducing kidney injury, as reflected by 40% lower plasma creatinine (1.17 ± 0.03 mg/dl) in the electric field–treated group as compared to the untreated control group (1.89 ± 0.06 mg/dl). In a mouse kidney transplantation model, renal graft function was improved by more than 50% with the application of the synchronization modulation electric field according to glomerular filtration rate measurements (85.40 ± 12.18 μl/min in the untreated group versus 142.80 ± 11.65 μl/min in the electric field–treated group). This technique for preserving Na/K pump function may have therapeutic potential not only for ischemic kidney injury but also for other diseases associated with Na/K pump dysfunction due to inadequate ATP supply.
POST-MYOCARDIAL INFARCTION VENTRICULAR SEPTAL DEFECT IN PATIENT WITH NON-OCCLUSIVE LEFT ANTERIOR DESCENDING ARTERY INFARCT
Authors: Noah Blaker, Afifah Khan, Marjorie Spitznagel, Chukwuemeka Obi, Terrence X. O’Brien
Journal: Journal of the American College of Cardiology (2022)
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options
Authors: Anne S. Tsao, Harvey I. Pass, Andreas Rimner, Aaron S. Mansfield
Journal: Journal of Clinical Oncology (2022)

Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a novel biomedical device approved for use with platinum-pemetrexed, and also for immunotherapy agents to be included as a frontline treatment option in unresectable disease. Although predictive biomarkers for systemic therapy are not currently in use in clinical practice, it is essential to correctly identify the MPM histology to determine an optimal treatment plan. Patients with nonepithelioid MPM may have a greater magnitude of benefit to dual immunotherapy checkpoint inhibitors and this regimen should be preferred in the frontline setting for these patients. However, all patients with MPM can derive benefit from immunotherapy treatments, and these agents should ultimately be used at some point during their treatment journey. There are ongoing studies in the frontline unresectable setting that may further define the frontline therapy space, but a critical area of research will need to focus on the immunotherapy refractory population. This review article will describe the new developments in the areas of biology with genomics and chromothripsis, and also focus on updates in treatment strategies in radiology, surgery, radiation, and medical oncology with cellular therapies. These recent innovations are generating momentum to find better therapies for this disease.
USING THE “SNORKEL TECHNIQUE” TO PROTECT THE LEFT MAIN CORONARY ARTERY DURING VALVE-IN-VALVE TRANSCATHETER AORTIC VALVE IMPLANTATION
Authors: Syed Yaseen Naqvi, Anas Jawaid, Sunil Prasad, Peter Knight, Frederick Ling, Craig R. Narins
Journal: Journal of the American College of Cardiology (2022)
PREVALENCE OF POTENTIAL TRIGGERS AND UNDERLYING MEDICAL CONDITIONS IN SPONTANEOUS CORONARY ARTERY DISSECTION: A REPORT OF THE ISCAD REGISTRY
Authors: Soo Hyun Kim, Sahar Naderi, Anna Grodzinsky, Heather L. Gornik, Bryan J. Wells, Angela Taylor, Jennifer Lewey, Connie Ng Hess, Stanislav Henkin, Daniella Kadian-Dodov, Gretchen L. Wells, Lori Tam, Clara Vitarello, Fahad Alkhalfan, Gerald Chi, C. Michael Gibson, Katherine Leon, Malissa J. Wood
Journal: Journal of the American College of Cardiology (2022)
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Authors: Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, Mikhail Dvorkin, Andreia Cristina de Melo, Yaroslav Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, Marina Nechaeva, Domenica Lorusso, Giovanni Scambia, David Cibula, Róbert Póka, Ana Oaknin, Tamar Safra, Beata Mackowiak-Matejczyk, Ling Ma, Daleen Thomas, Kevin K Lin, Karen McLachlan, Sandra Goble, Amit M Oza
Journal: The Lancet Oncology (2022)
Comparative Implementation of a Brief App-Directed Protocol for Delirium Identification by Hospitalists, Nurses, and Nursing Assistants
Authors: Edward R. Marcantonio, Donna M. Fick, Yoojin Jung, Sharon K. Inouye, Marie Boltz, Douglas L. Leslie, Erica K. Husser, Priyanka Shrestha, Amber Moore, Kimberlyann Sulmonte, Jonathan Siuta, Malaz Boustani, Long H. Ngo
Journal: Annals of Internal Medicine (2021)

Systematic screening improves delirium identification among hospitalized older adults. Little data exist on how to implement such screening.To test implementation of a brief app-directed protocol for delirium identification by physicians, nurses, and certified nursing assistants (CNAs) in real-world practice relative to a research reference standard delirium assessment (RSDA).Prospective cohort study.Large urban academic medical center and small rural community hospital.527 general medicine inpatients (mean age, 80 years; 35% with preexisting dementia) and 399 clinicians (53 hospitalists, 236 nurses, and 110 CNAs).On 2 study days, enrolled patients had an RSDA. Subsequently, CNAs performed an ultra-brief 2-item screen (UB-2) for delirium, whereas physicians and nurses performed a 2-step protocol consisting of the UB-2 followed in those with a positive screen result by the 3-Minute Diagnostic Assessment for the Confusion Assessment Method.Delirium was diagnosed in 154 of 924 RSDAs (17%) and in 114 of 527 patients (22%). The completion rate for clinician protocols exceeded 97%. The CNAs administered the UB-2 in a mean of 62 seconds (SD, 51). The 2-step protocols were administered in means of 104 seconds (SD, 99) by nurses and 106 seconds (SD, 105) by physicians. The UB-2 had sensitivities of 88% (95% CI, 72% to 96%), 87% (CI, 73% to 95%), and 82% (CI, 65% to 91%) when administered by CNAs, nurses, and physicians, respectively, with specificities of 64% to 70%. The 2-step protocol had overall accuracy of 89% (CI, 83% to 93%) and 87% (CI, 81% to 91%), with sensitivities of 65% (CI, 48% to 79%) and 63% (CI, 46% to 77%) and specificities of 93% (CI, 88% to 96%) and 91% (CI, 86% to 95%), for nurses and physicians, respectively. Two-step protocol sensitivity for moderate to severe delirium was 78% (CI, 54% to 91%).Two sites; limited diversity.An app-directed protocol for delirium identification was feasible, brief, and accurate, and CNAs and nurses performed as well as hospitalists.National Institute on Aging.
An Intramedullary Enigma
Authors: Nayan Lamba, Danielle S. Bitterman
Journal: JAMA Oncology (2022)

A woman in her 60s was diagnosed with high-grade leiomyosarcoma of the uterus, which had been treated with hysterectomy and bilateral salpingo-oophorectomy, and subsequently had relapsed in the liver and spine. What is your diagnosis?
Characterization of a Newly Emerging HIV-1 Second-Generation Recombinant Form (CRF125_0107) Among Heterosexuals in Yunnan, China
Authors: Meng Xiao, Yue Feng, Li Gao, Cuixian Yang, Jiafa Liu, Meilan He, Jianjian Li, Mi Zhang, Xingqi Dong, Xueshan Xia
Journal: Journal of Infection (2022)
Brain-targeting, acid-responsive antioxidant nanoparticles for stroke treatment and drug delivery
Authors: Shenqi Zhang, Bin Peng, Zeming Chen, Jiang Yu, Gang Deng, Youmei Bao, Chao Ma, Fengyi Du, Wendy C. Sheu, W. Taylor Kimberly, J. Marc Simard, Daniel Coman, Qianxue Chen, Fahmeed Hyder, Jiangbing Zhou, Kevin N. Sheth
Journal: Bioactive Materials (2022)

Stroke is the leading cause of death and disability. Currently, there is no effective pharmacological treatment for this disease, which can be partially attributed to the inability to efficiently deliver therapeutics to the brain. Here we report the development of natural compound-derived nanoparticles (NPs), which function both as a potent therapeutic agent for stroke treatment and as an efficient carrier for drug delivery to the ischemic brain. First, we screened a collection of natural nanomaterials and identified betulinic acid (BA) as one of the most potent antioxidants for stroke treatment. Next, we engineered BA NPs for preferential drug release in acidic ischemic tissue through chemically converting BA to betulinic amine (BAM) and for targeted drug delivery through surface conjugation of AMD3100, a CXCR4 antagonist. The resulting AMD3100-conjugated BAM NPs, or A-BAM NPs, were then assessed as a therapeutic agent for stroke treatment and as a carrier for delivery of NA1, a neuroprotective peptide. We show that intravenous administration of A-BAM NPs effectively improved recovery from stroke and its efficacy was further enhanced when NA1 was encapsulated. Due to their multifunctionality and significant efficacy, we anticipate that A-BAM NPs have the potential to be translated both as a therapeutic agent and as a drug carrier to improve the treatment of stroke.
PERCUTANEOUS MITRAL VALVE-IN-VALVE REPLACEMENT FOR SEVERE PROSTHETIC MITRAL VALVE STENOSIS AND HIGH RISK FOR OUTFLOW OBSTRUCTION USING RADIOFREQUENCY ABLATION
Authors: Emily Hiltner, Ashish Shukla, Pratik B. Patel, Mark Russo, Ankur Sethi
Journal: Journal of the American College of Cardiology (2022)
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O<sup>6</sup>-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
Authors: Federica Morano, Alessandra Raimondi, Filippo Pagani, Sara Lonardi, Lisa Salvatore, Chiara Cremolini, Sabina Murgioni, Giovanni Randon, Federica Palermo, Lorenzo Antonuzzo, Nicoletta Pella, Patrizia Racca, Michele Prisciandaro, Monica Niger, Francesca Corti, Francesca Bergamo, Alberto Zaniboni, Margherita Ratti, Michele Palazzo, Celeste Cagnazzo, Maria Alessandra Calegari, Federica Marmorino, Iolanda Capone, Elena Conca, Adele Busico, Silvia Brich, Elena Tamborini, Federica Perrone, Massimo Di Maio, Massimo Milione, Maria Di Bartolomeo, Filippo de Braud, Filippo Pietrantonio
Journal: Journal of Clinical Oncology (2022)

This is a multicenter, single-arm phase II trial evaluating the efficacy and safety of an immune-sensitizing strategy with temozolomide priming followed by a combination of low-dose ipilimumab and nivolumab in patients with microsatellite-stable (MSS) and O6-methylguanine-DNA methyltransferase (MGMT)-silenced metastatic colorectal cancer (mCRC).Patients with pretreated mCRC were centrally prescreened for MSS status and MGMT silencing (ie, lack of MGMT expression by immunohistochemistry plus MGMT methylation by pyrosequencing). Eligible patients received two priming cycles of oral temozolomide 150 mg/sqm once daily, days 1-5, once every 4 weeks (first treatment part) followed, in absence of progression, by its combination with ipilimumab 1 mg/kg once every 8 weeks and nivolumab 480 mg once every 4 weeks (second treatment part). The primary end point was the 8-month progression-free survival (PFS) rate calculated from enrollment in patients who started the second treatment part, with ≥ 4 out of 27 subjects progression-free by the 8-month time point as decision rule.Among 716 prescreened patients, 204 (29%) were molecularly eligible and 135 started the first treatment part. Among these, 102 (76%) were discontinued because of death or disease progression on temozolomide priming, whereas 33 patients (24%) who achieved disease control started the second treatment part and represented the final study population. After a median follow-up of 23.1 months (interquartile range, 14.9-24.6 months), 8-month PFS rate was 36%. Median PFS and overall survival were 7.0 and 18.4 months, respectively, and overall response rate was 45%. Grade 3-4 immune-related adverse events were skin rash (6%), colitis (3%), and hypophysitis (3%). No unexpected adverse events or treatment-related deaths were reported.The MAYA study provided proof-of-concept that a sequence of temozolomide priming followed by a combination of low-dose ipilimumab and nivolumab may induce durable clinical benefit in MSS and MGMT-silenced mCRC.